Prevent IDIQ mato RFP
Awarded Award Notice Posted
- Solicitation number
- 75N91024D00006
- Agency
- National Cancer Institute National Institutes of Health, Department of Health and Human Services
- Awarded
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N91024D00006-75N91024D00006_75N91024F00001
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- New York, New York 10065, United States
Notice details come from SAM.gov. Updated .
About this opportunity
This Award Notice announces a contract awarded under the PREVENT IDIQ MATO RFP to WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY. The contract, valued at $149,995,000, will support preclinical efficacy and intermediate endpoint biomarkers services under the PREVENT Cancer Preclinical Drug Development Program, which provides structured drug and vaccine development services from discovery through clinical trials. The services procured are part of an IDIQ pool established by the National Cancer Institute within the National Institutes of Health, Department of Health and Human Services.
Notice text
2 versions
Update #2 · Latest ·
PREVENT EFFICACY Pool: This contract supports the PREVENT Cancer Preclinical Drug Development Program,
which provides a structured approach to drug and vaccine development, from discovery to the clinic. This contract is a
part of a multiple-award Indefinite Delivery Indefinite Quantity (IDIQ) pool to procure services related to Preclinical
Efficacy and Intermediate Endpoint Biomarkers, which is also referred to as the Efficacy Pool.
Awarded contract 75N91024D00006 to WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY for 149995000.00 on 2024-01-24.
Update #1 ·
PREVENT EFFICACY Pool: This contract supports the PREVENT Cancer Preclinical Drug Development Program,
which provides a structured approach to drug and vaccine development, from discovery to the clinic. This contract is a
part of a multiple-award Indefinite Delivery Indefinite Quantity (IDIQ) pool to procure services related to Preclinical
Efficacy and Intermediate Endpoint Biomarkers, which is also referred to as the Efficacy Pool.
Awarded contract 75N91024D00006 to WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY for 149995000.00 on 2024-01-23.
Notice history
| Notice | Type | Posted |
|---|---|---|
| PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for cGMP Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing | Award Notice | |
| PREVENT Preclinical Efficacy & Endpoint Biomarkers | Award Notice | |
| PREVENT Preclinical Efficacy & Endpoint Biomarkers | Award Notice | |
| Prevent IDIQ mato RFP | Award Notice | |
| Prevent IDIQ mato RFP | Solicitation | |
| Prevent IDIQ mato RFP | Pre-Solicitation |
And 7 more award notices.
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity